440 related articles for article (PubMed ID: 26525434)
1. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
Ward MG; Irving PM; Sparrow MP
World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
[TBL] [Abstract][Full Text] [Related]
2. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
4. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
Johnson CM; Dassopoulos T
Curr Gastroenterol Rep; 2018 Sep; 20(11):53. PubMed ID: 30267281
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.
Xu Z; Davis HM; Zhou H
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S60-74. PubMed ID: 25707965
[TBL] [Abstract][Full Text] [Related]
6. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
7. De-escalation of Therapy in Inflammatory Bowel Disease.
Frias Gomes C; Colombel JF; Torres J
Curr Gastroenterol Rep; 2018 Jul; 20(8):35. PubMed ID: 29961926
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era.
Campos S; Portela F; Sousa P; Sofia C
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1313-9. PubMed ID: 27501126
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis.
Chen L; Xu CJ; Wu W; Ding BJ; Liu ZJ
J Dig Dis; 2021 Jul; 22(7):408-418. PubMed ID: 34048629
[TBL] [Abstract][Full Text] [Related]
10. Which patients with inflammatory bowel disease should receive combination therapy?
Cross RK
Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):715-7. PubMed ID: 25912620
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort.
Varma P; Rajadurai AS; Holt DQ; Devonshire DA; Desmond CP; Swan MP; Nathan D; Shelton ET; Prideaux L; Sorrell C; Rusli F; Crantock LRF; Dev A; Ratnam DT; Pianko S; Moore GT
Intern Med J; 2019 Jun; 49(6):753-760. PubMed ID: 30381884
[TBL] [Abstract][Full Text] [Related]
12. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
14. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
Papamichael K; Osterman MT; Siegel CA; Melmed GY; Dubinsky MC; Colombel JF; Hanauer SB; Cheifetz AS
Gastroenterology; 2018 Mar; 154(4):1201-1202. PubMed ID: 29432749
[No Abstract] [Full Text] [Related]
15. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases.
Yarur AJ; Rubin DT
Inflamm Bowel Dis; 2015 Jul; 21(7):1709-18. PubMed ID: 25901974
[TBL] [Abstract][Full Text] [Related]
17. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
18. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place.
van Hoeve K; Vermeire S
Paediatr Drugs; 2020 Oct; 22(5):449-461. PubMed ID: 32797366
[TBL] [Abstract][Full Text] [Related]
19. When to Start Immunomodulators in Inflammatory Bowel Disease?
Sharara AI
Dig Dis; 2016; 34(1-2):125-31. PubMed ID: 26982809
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease.
Vasudevan A; Gibson PR; Van Langenberg DR
Inflamm Bowel Dis; 2019 Aug; 25(9):1462-1473. PubMed ID: 30689858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
